TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01568164

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PliCath HF System
Description: This study is a multi-center, prospective, single-armed, study designed to evaluate the safety and efficacy of the BioVentrix PliCath HF System for left ventricular volume restoration in patients with ischemic cardiomyopathy.
Study: NCT03604419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PB-119 100 μg+ Glucophage®
Description: Each patient will subsequently be randomized within the designated cohort to active drug or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PB-119 100 μg+ Glucophage®
Description: Each patient will subsequently be randomized within the designated cohort to active drug or placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PB-119 100 μg+ Glucophage®
Description: Each patient will subsequently be randomized within the designated cohort to active drug or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PB-119 150 μg+ Glucophage®
Description: Each patient will subsequently be randomized within the designated cohort to active drug or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PB-119 150 μg+ Glucophage®
Description: Each patient will subsequently be randomized within the designated cohort to active drug or placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PB-119 150 μg+ Glucophage®
Description: Each patient will subsequently be randomized within the designated cohort to active drug or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PB-119 200 μg+ Glucophage®
Description: Each patient will subsequently be randomized within the designated cohort to active drug or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PB-119 200 μg+ Glucophage®
Description: Each patient will subsequently be randomized within the designated cohort to active drug or placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PB-119 200 μg+ Glucophage®
Description: Each patient will subsequently be randomized within the designated cohort to active drug or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PB-119 placebo + Glucophage®
Description: Each patient will subsequently be randomized within the designated cohort to active drug or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PB-119 placebo + Glucophage®
Description: Each patient will subsequently be randomized within the designated cohort to active drug or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PB-119 placebo + Glucophage®
Description: Each patient will subsequently be randomized within the designated cohort to active drug or placebo
Study: NCT04055402

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ecological momentary assessments
Description: The staff will help the participants in the EMA group to install and set up the EMA App. The briefing will also emphasise the role of EMA participants that they should perform their normal activities as usual instead of finding out the alcohol advertisements and PADC intentionally. Within 2 weeks after completing the baseline survey, participants in EMA group will complete 5 EMAs prompted regularly every day for 14 consecutive days. The participants will then be contacted for a follow-up survey 2 weeks after the completion of EMA.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Completion of a baseline questionnaire and a 1-month follow-up survey.
Study: NCT00405678

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: Subjects receiving chemo with exercise training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: Subjects receiving chemo with exercise training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chemo only
Description: Subjects receiving chemo only
Study: NCT01759199

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation assessed with six-minute walk test and six-minute stepper test
Study: NCT04494659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famitinib capsule
Description: single dose and co-administrated with Rifampicin capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin capsule
Description: repeated doses of Rifampicin capsule
Study: NCT01104207

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation (rTMS)
Description: rTMS involves application of electromagnetic pulses through a coil to the subject's scalp. Some of the electromagnetic energy is transmitted to underlying neural tissue. The goal for this study: 1 Hz rTMS will suppress neural activity responsible for tinnitus perception.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: placebo rTMS
Description: placebo rTMS
Study: NCT02309827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600 or Placebo
Description: PF-06651600 or placebo will be administered as an extemporaneously prepared solution in each cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600 or Placebo
Description: PF-06651600 or placebo will be administered as an extemporaneously prepared solution in each cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600 or Placebo
Description: PF-06651600 or placebo will be administered as an extemporaneously prepared solution in each cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600 or Placebo
Description: PF-06651600 or placebo will be administered as an extemporaneously prepared solution in each cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600 or Placebo
Description: PF-06651600 or placebo will be administered as an extemporaneously prepared solution in each cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600 or Placebo
Description: PF-06651600 or placebo will be administered as an extemporaneously prepared solution in each cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600 or Placebo
Description: PF-06651600 or placebo will be administered as an extemporaneously prepared solution in each cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600 or Placebo
Description: PF-06651600 or placebo will be administered as an extemporaneously prepared solution in each cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600 or Placebo
Description: PF-06651600 or placebo will be administered as an extemporaneously prepared solution in each cohort.
Study: NCT04848948

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Calory Restriction (F.X. Mayr & VLCD)
Description: VLCD restricts calory intake to 630 - 700 kcal per day (20% fat, 34% protein, 46% carbohydrates).~F.X. Mayr diet similarly applies calorie restriction to 700 - 800 kcal per day and includes daily ingestion of isotonic magnesium sulfate solution.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Calory Restriction (F.X. Mayr & VLCD)
Description: VLCD restricts calory intake to 630 - 700 kcal per day (20% fat, 34% protein, 46% carbohydrates).~F.X. Mayr diet similarly applies calorie restriction to 700 - 800 kcal per day and includes daily ingestion of isotonic magnesium sulfate solution.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Calory Restriction (F.X. Mayr & VLCD)
Description: VLCD restricts calory intake to 630 - 700 kcal per day (20% fat, 34% protein, 46% carbohydrates).~F.X. Mayr diet similarly applies calorie restriction to 700 - 800 kcal per day and includes daily ingestion of isotonic magnesium sulfate solution.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Calory Restriction (F.X. Mayr & VLCD)
Description: VLCD restricts calory intake to 630 - 700 kcal per day (20% fat, 34% protein, 46% carbohydrates).~F.X. Mayr diet similarly applies calorie restriction to 700 - 800 kcal per day and includes daily ingestion of isotonic magnesium sulfate solution.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biofeedback
Description: Three sessions of biofeedback (50 minutes) over a time frame of 14 days, aimed at improving biological functions and especially heart-rate-variability under stress condition.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biofeedback
Description: Three sessions of biofeedback (50 minutes) over a time frame of 14 days, aimed at improving biological functions and especially heart-rate-variability under stress condition.
Study: NCT04078048

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Antioxidants (Vitamin C, E )
Description: For eight weeks, Vitamin C group was intervened with tablet vitamin c 500 mg once a day ,vitamin E group was intervened with Tablet vitamin E 600 I U twice a day.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Antioxidants (Vitamin C, E )
Description: For eight weeks, Vitamin C group was intervened with tablet vitamin c 500 mg once a day ,vitamin E group was intervened with Tablet vitamin E 600 I U twice a day.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Antioxidants (Vitamin C, E )
Description: For eight weeks, Vitamin C group was intervened with tablet vitamin c 500 mg once a day ,vitamin E group was intervened with Tablet vitamin E 600 I U twice a day.
Study: NCT04458649

Intervention type: DEVICE
Intervention: Dexcom continuous glucose monitor
Description: Measurement of interstitial glucose

Intervention type: DEVICE
Intervention: Dexcom continuous glucose monitor
Description: Measurement of interstitial glucose
Study: NCT01532622

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Blueberry Powder
Description: Patients will take 30 grams of blueberry powder daily for up to 30 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Powder
Description: Patients will take 30 grams of placebo powder daily for up to 30 days.
Study: NCT02438878

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baby Behavior
Study: NCT02402348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study: NCT06193395

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: No intervention, only clinical testing of questionnaire
Study: NCT02291900

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: core decompression
Description: retrograd drilling of the avascular talar necrosis, followed by osseous autograft

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: core decompression
Description: retrograd drilling of the avascular talar necrosis, followed by osseous autograft
Study: NCT01768806

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PLAY Project Intervention for Autism
Description: Children diagnosed with autism were recruited to the PLAY Project Intervention grant and assigned to a community standard arm (CS) or a CS plus PLAY Project arm of the study. Those in the PLAY Project arm of the study received a one time per month home visit to train caregivers in the PLAY Project methods including video feedback and caregivers also receive mid month feedback based on the video review of interaction.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Special education pre-school
Description: Special education preschool services included 10-12 hours per week of educational services including speech and language and occupational therapy
Study: NCT05906810

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical periodontal treatment
Description: Subgingival biofilm ultrasonic debridement

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal treatment
Description: Subgingival biofilm ultrasonic debridement
Study: NCT01170286

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Whole peanut extract
Description: Four different doses of whole peanut extract expressed as micrograms (mcg) of peanut proteins (20, 100, 250, 500 mcg) and two different dosing regimen (epicutaneous application for 24 hours every 24 hours and epicutaneous application for 48 hours every 48 hours) will be tested for determination of the maximum tolerated dose during a 2-week treatment period.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo formulation
Description: Matching placebo at two different dosing regimen (epicutaneous application for 24 hours every 24 hours and epicutaneous application for 48 hours every 48 hours) will be tested in parallel to the peanut proteins doses for determination of the maximum tolerated dose during a 2-week treatment period.
Study: NCT02242292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyoscine butylbromide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01701726

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: In each session, acupuncture are applied bilaterally. Except the acupoints around the neck(ST9.GB20.non-acupoints 4) ,6 auxiliary needles will be punctured at 2mm lateral to each acupoints or non-acupoints.as to auxiliary needle we will not do any manipulation. We use transcutaneous electric acupoints stimulation to stimulate the acupoints and non-acupoints.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: In contrast to acupuncture, sham acupuncture is given at 4 sham points with skin penetration. Electroacupuncture is also applied.
Study: NCT02490488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Masitinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03187678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: i.v. selexipag
Description: Selexipag for intravenous administration, twice daily as an infusion over 87 min. The dose is individualized for each subject to correspond to his/her current oral dose of Uptravi®.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral selexipag (Uptravi)
Description: Uptravi is used as an auxiliary medicinal product, as part of the PAH standard treatment and administered according to the local prescribing information
Study: NCT04315857

Intervention type: OTHER
Intervention: interstitial glycaemia
Description: Continuous measurement of interstitial blood glucose during the first 15 days of the first two chemotherapy courses.
Study: NCT02079753

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inogen
Description: single pulse dose concentrator (Inogen One G2 portable. Inogen) device for 24 hours

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Combination system of a portable and a stationary device.
Description: Combination system of a portable and a stationary device (reservoir of liquid oxygen Liberator 30, Caire and a liquid Stroller oxygen pack Caire for patients using previously liquid oxygen, or a VisionAire5 Airsep stationary concentrator and an Inogen One G2 portable Inogen concentrator for patients using previously concentrators)
Study: NCT01399736

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FFR-guided revascularisation strategy
Description: FFR-guided revascularisation strategy

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: randomised to guidelines group
Description: Staged revascularisation by proven ischemia or persistence of symptoms of angina
Study: NCT03947138

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC3107
Description: BCG Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC3107
Description: BCG Vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Intradermal BCG SSI inj.
Description: BCG Vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Intradermal BCG SSI inj.
Description: BCG Vaccine
Study: NCT04066309

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neodent GM Helix Implant
Description: 4.0x10 mm Neodent GM Helix Implants will be placed 2mm subcrestally (in relation to the buccal bone plate) in the posterior region of the maxilla, under local anesthesia and with adequate bone bed preparation, as recommended by the manufacturer, using the guided surgery technique.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neodent GM Helix Implant
Description: 4.0x10 mm Neodent GM Helix Implants will be placed 2mm subcrestally (in relation to the buccal bone plate) in the posterior region of the maxilla, under local anesthesia and with adequate bone bed preparation, as recommended by the manufacturer, using the guided surgery technique.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GM Customizable Healing Abutment
Description: Customizable healing abutments will be placed at the time of implant placement.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GM Pro PEEK Abutment
Description: Placement of temporary single prostheses (early loading), over temporary abutments.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GM Exact Titanium Base
Description: Insertion of the final abutment (Titanium Base and Zirconia Coping), following the digital workflow.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GM Exact Titanium Base
Description: Insertion of the final abutment (Titanium Base and Zirconia Coping), following the digital workflow.
Study: NCT05805553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: 2mg/kg/day in 3-4 dividd doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: 2mg/kg/day in 3-4 dividd doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nandrolone Decanoate
Description: 1mg/kg weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nandrolone Decanoate
Description: 1mg/kg weekly
Study: NCT00379340

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dactinomycin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate Liposome
Description: Given IV
Study: NCT01870661

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Long axis IV placement with ultrasound
Description: Peripheral IV placement with the ultrasound probe viewing the vessel in the long axis.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Short axis IV placement with ultrasound
Description: Peripheral IV placement with the ultrasound probe viewing the vessel in the short axis.
Study: NCT01601197

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tactile stimulation
Description: Immunizer will rub the ipsilateral limb before, during and after immunization injection(s)
Study: NCT05159609

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Closed loop auditory stimulus
Description: 50ms of low volume pink noise delivered during slow wave sleep

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Closed loop auditory stimulus
Description: 50ms of low volume pink noise delivered during slow wave sleep
Study: NCT06371248

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Steady Feet
Description: Steady Feet is a three-month progressive exercise-based single-component intervention spanning twenty-four sessions, with a focus on enhancing balance, mobility, and strength among community-dwelling older adults at risk of falls.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care for fall prevention
Description: CGH's usual care for fall prevention, which include fall prevention materials and advice.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care for fall prevention
Description: CGH's usual care for fall prevention, which include fall prevention materials and advice.
Study: NCT00623207

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atropine
Description: I.V Atropine 0.5mg up to 2 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine
Description: I.V Atropine 0.5mg up to 2 mg
Study: NCT00658398

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Interactive Computer Program to prevent alcohol misuse.
Description: Interactive Computer Program with questionnaires, video and informations

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive Computer Program to prevent alcohol misuse.
Description: Interactive Computer Program with questionnaires, video and informations
Study: NCT02070237

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Enoxaparin will be given in either once daily or twice daily doses. One arm will receive 40 mg enoxaparin subcutaneous injection daily. The other arm will receive 0.5 mg/kg dosed subcutaneously twice daily. This medication will be started 8-12 hours after cesarean section and will be continued while the patient is admitted. It will be stopped at the time of discharge.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Enoxaparin will be given in either once daily or twice daily doses. One arm will receive 40 mg enoxaparin subcutaneous injection daily. The other arm will receive 0.5 mg/kg dosed subcutaneously twice daily. This medication will be started 8-12 hours after cesarean section and will be continued while the patient is admitted. It will be stopped at the time of discharge.
Study: NCT02183064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NSAID
Study: NCT01941030

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orbital Atherectomy System
Description: Orbital atherectomy (OA) is performed prior to adjunctive balloon angioplasty (BA)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Balloon Angioplasty
Description: Type of balloon selected is driven by preference of the operator.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Balloon Angioplasty
Description: Type of balloon selected is driven by preference of the operator.